1-3 of 3
Malte von Bonin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Letter

Malte von Bonin, Katharina Moll, Michael Kramer, Uta Oelschlägel, Martin Wermke, Christoph Röllig, Christian Thiede, Gerhard Ehninger, Alwin Krämer, Carsten Müller-Tidow, Ioannis Mitroulis, Martin Bornhäuser
Journal: Cancer Research
Cancer Res (2018) 78 (21): 6339–6341.
https://doi.org/10.1158/0008-5472.CAN-18-0642
Published: 01 November 2018
View article titled, JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Letter
Open the PDF for JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Letter in another window
Journal Articles

Abstract 2313: Improved killing of tumor cells by a novel flexible antibody-based modular T cell retargeting system

Armin Ehninger, Marc Cartellieri, Anja Feldmann, Claudia Arndt, Stefanie Koristka, Simon Loff, Malte von Bonin, Gerhard Ehninger, Michael Bachmann
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2313.
https://doi.org/10.1158/1538-7445.AM2016-2313
Published: 15 July 2016
View article titled, Abstract 2313: Improved killing of tumor cells by a novel flexible antibody-based modular T cell retargeting system
Journal Articles

Activity and induction of apoptosis of the tyrosine kinase inhibitor AMN107 in bcr-abl + cell lines and in imatinib resistant primary cells from CML patients

Philipp Le Coutre, Gökben Baskaynak, Ingo Tamm, Jörg Westermann, Justus Duyster, Malte Von Bonin, Stefan Pursche, Petra Mayer, Paul Manley, Jürgen Mestan, Eberhard Schleyer, Bernd Dörken
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1408–1409.
Published: 01 May 2005
View article titled, Activity and induction of apoptosis of the tyrosine kinase inhibitor AMN107 in bcr-abl + cell lines and in imatinib resistant primary cells from CML patients